Neoplasms, Colorectal Completed Phase 2 Trials for Cetuximab (DB00002)

Also known as: Colorectal Neoplasms / Colorectal Neoplasm / Neoplasms,Colorectal

IndicationStatusPhase
DBCOND0036298 (Neoplasms, Colorectal)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00044863Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal CarcinomaTreatment
NCT00055419A Study of Cetuximab in Patients Who Have Stage IV Colorectal CancerTreatment
NCT00083720Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to ChemotherapyTreatment
NCT01152437A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal CancerTreatment
NCT01450319Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) GenotypeTreatment